Flexibility as Competitive Advantage
Mega-merged companies have to find twice as many drugs or drugs which are twice as valuable. But there are fewer such opportunities as managed care lifts higher innovation hurdles for manufacturers, particularly in developing the widely-used chroniccare medicines that form the basis of most drug companies' profit statements.
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.